文献速递肺栓塞与肺血管病呼吸危重症与机械通气

新肺动脉高压定义对心脏移植结局的影响:扩展血流动力学风险谱

Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding the Hemodynamic Risk Profile.
PubMed 文献 · Chest · 2019-08-22

该研究基于美国器官共享网络数据库,分析1996至2015年32465例成人心脏移植受者,其中12257例(38%)平均肺动脉压(mPAP)<25 mm Hg。多变量模型显示,肺血管阻力(PVR)独立关联30天死亡风险增加(HR 1.16;95%CI 1.05-1.27;P<.01),但与条件1年死亡率无关(HR 1.03;95%CI 0.94-1.12;P=.55)。在mPAP<25 mm Hg者中,PVR≥3 WU与30天死亡率绝对增加1.9%,风险与PVR≥3 WU且mPAP≥25 mm Hg者相似。结论支持新肺动脉高压定义的有效性。

要点

  • 心脏移植受者中38%的mPAP<25 mm Hg,但PVR升高仍与30天死亡风险增加独立相关。
  • mPAP<25 mm Hg者中PVR≥3 WU的30天死亡率绝对增加1.9%,风险与mPAP≥25 mm Hg且PVR≥3 WU者相似。
  • PVR与条件1年死亡率无显著独立关联,提示风险主要集中在术后早期。

核心结论

  • 即使mPAP<25 mm Hg,移植前PVR升高仍与心脏移植后30天死亡风险显著增加独立相关,支持新肺动脉高压定义将较低肺动脉压伴PVR升高纳入。

研究设计与样本

  • 回顾性队列研究,查询美国器官共享网络数据库,纳入1996至2015年接受首次心脏移植的成人受者,共32465例。
  • 受者按mPAP<25 mm Hg与≥25 mm Hg分组,在mPAP<25 mm Hg组中先进行探索性单变量分析筛选风险因素,再构建简约多变量Cox比例风险模型评估PVR与结局的独立关联。

主要发现

  • 研究期间32465例接受心脏移植,其中12257例(38%)mPAP<25 mm Hg。
  • mPAP<25 mm Hg组中位年龄55岁(四分位距47-62),中位PVR为1.5 Wood单位(WU)(四分位距1-2.2)。
  • 多变量控制混杂因素后,PVR与30天死亡风险增加独立相关(HR 1.16;95%CI 1.05-1.27;P<.01)。
  • PVR与条件1年死亡率无显著独立关联(HR 1.03;95%CI 0.94-1.12;P=.55)。
  • mPAP<25 mm Hg者中,PVR≥3 WU与30天死亡率绝对增加1.9%,风险与PVR≥3 WU且mPAP≥25 mm Hg者相似。

关键数值与推荐

  • 新肺动脉高压定义:在肺血管阻力升高背景下纳入较低肺动脉压。
  • mPAP<25 mm Hg组中,PVR≥3 WU与30天死亡率绝对增加1.9%相关。

临床怎么用

  • 心脏移植术前评估应重视PVR,即使mPAP<25 mm Hg,PVR≥3 WU仍提示术后30天死亡风险增加。
  • 新肺动脉高压定义有助于识别mPAP较低但PVR升高的高危移植受者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At the recent 6th World Symposium on Pulmonary Hypertension (PH), the definition of PH was redefined to include lower pulmonary artery pressures in the setting of elevated pulmonary vascular resistance (PVR). However, the relevance of this change to subjects with PH due to left-heart disease as well as the preoperative assessment of heart transplant (HT) recipients is unknown. METHODS: The United Network for Organ Sharing database was queried to identify adult recipients who underwent primary HT from 1996 to 2015. Recipients were subdivided into those with mean pulmonary artery pressure (mPAP) < 25 mm Hg and ≥ 25 mm Hg. Exploratory univariable analysis was undertaken to identify candidate risk factors associated with 30-day and 1-year survival (conditional on 30-day survival) in recipients with mPAP < 25 mm Hg, and subsequently, parsimonious multivariable Cox proportional hazards models were constructed to assess the independent association with PVR. RESULTS: Over the study period, 32,465 patients underwent HT, including 12,257 (38%) with mPAP < 25 mm Hg. The median age was 55 years (interquartile range, 47-62) and the median PVR was 1.5 Wood units (WU) (interquartile range, 1-2.2) in recipients with mPAP < 25 mm Hg. After controlling for confounders, PVR was independently associated with increased risk for 30-day mortality (hazard ratio, 1.16; 95% CI, 1.05-1.27; P < .01), but not conditional 1-year mortality (hazard ratio, 1.03; 95% CI, 0.94-1.12; P = .55). PVR ≥ 3 WU was associated with an absolute 1.9% increase in 30-day mortality in those with mPAP < 25 mm Hg, a similar risk to recipients with PVR ≥ 3 WU and mPAP ≥ 25 mm Hg. CONCLUSIONS: Elevated PVR remains associated with a significant increase in the hazard for 30-day mortality after cardiac transplantation, even in the setting of lower pulmonary artery pressures. These data support the validity of the new definition of pulmonary hypertension.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Crawford TC, Leary PJ, Fraser CD, et al. Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding the Hemodynamic Risk Profile. Chest. 2019. PMID: 31446063. doi:10.1016/j.chest.2019.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。